Brief: Hoth Therapeutics Reaches EMA Milestone for HT-001 Phase II Trial Targeting EGFRi-Linked Skin Toxicities
10/09/2025 13:30
Sept 10 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS SECURES KEY EUROPEAN REGULATORY MILESTONE WITH EMA SUBMISSION FOR PHASE II TRIAL OF HT-001 IN CANCER PATIENTS SUFFERING FROM EGFRI-INDUCED SKIN TOXICITIES Source text: ID:nPn4wb2pta Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology